Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study is for patients with a type of cancer called carcinoma of unknown primary site
(CUP), meaning that the site of the body where the tumor has originated is not clear.
Currently, carcinoma of unknown primary site (CUP) accounts for about 5% of all newly
diagnosed malignancies. The stage of the tumor is such that it is not treatable by surgery.
Currently, the standard treatment for such a type of cancer at that stage is chemotherapy.
However, the overall prognosis for patients with metastatic CUP remains poor, even if treated
with conventional chemotherapy. Through ongoing research at medical centers around the world,
doctors are trying to improve on the presently available chemotherapy regimens. The purpose
of the investigators' study is similar: it is trying to determine whether a combination of
three chemotherapy drugs - carboplatin, gemcitabine, and capecitabine - will improve the
treatment of patients with metastatic CUP. The reason the investigators are interested in the
above combination of chemotherapy agents is that each one of them is already used in patients
with a variety of specific tumors, such as lung cancer, breast cancer, pancreatic cancer,
colon cancer, etc.
This research study will help determine whether the combination of carboplatin, gemcitabine
and capecitabine can be used and is effective in patients with carcinoma of unknown primary
site.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center